SG Americas Securities LLC Has $4.53 Million Holdings in Revvity, Inc. (NYSE:RVTY)

SG Americas Securities LLC decreased its position in Revvity, Inc. (NYSE:RVTY) by 18.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,568 shares of the company’s stock after selling 9,446 shares during the quarter. SG Americas Securities LLC’s holdings in Revvity were worth $4,528,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in RVTY. Gladius Capital Management LP bought a new position in Revvity during the 3rd quarter worth $32,000. Continuum Advisory LLC increased its position in Revvity by 2,972.7% during the third quarter. Continuum Advisory LLC now owns 338 shares of the company’s stock worth $43,000 after acquiring an additional 327 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in Revvity by 55.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company’s stock worth $43,000 after purchasing an additional 138 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Revvity by 74.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock valued at $41,000 after purchasing an additional 167 shares during the period. Finally, Avior Wealth Management LLC increased its holdings in shares of Revvity by 7,980.0% during the third quarter. Avior Wealth Management LLC now owns 404 shares of the company’s stock worth $52,000 after purchasing an additional 399 shares during the period. Institutional investors and hedge funds own 86.65% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on RVTY. Sanford C. Bernstein downgraded Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price for the company. in a research report on Friday, January 10th. Raymond James reduced their target price on Revvity from $146.00 to $140.00 and set an “outperform” rating on the stock in a report on Tuesday. Robert W. Baird lifted their target price on Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Barclays reduced their price target on shares of Revvity from $140.00 to $135.00 and set an “overweight” rating on the stock in a research note on Monday, November 25th. Finally, Leerink Partners increased their price objective on shares of Revvity from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Five research analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $132.00.

Revvity Trading Up 0.2 %

NYSE RVTY opened at $123.27 on Friday. Revvity, Inc. has a 52 week low of $97.32 and a 52 week high of $129.50. The business has a 50 day moving average price of $115.16 and a 200-day moving average price of $117.98. The company has a quick ratio of 2.97, a current ratio of 3.56 and a debt-to-equity ratio of 0.40. The company has a market cap of $15.00 billion, a price-to-earnings ratio of 59.55, a P/E/G ratio of 3.67 and a beta of 1.03.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.15. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The firm had revenue of $684.10 million during the quarter, compared to analysts’ expectations of $679.66 million. During the same period last year, the company earned $1.18 earnings per share. The business’s revenue was up 2.1% on a year-over-year basis. As a group, equities analysts expect that Revvity, Inc. will post 4.84 earnings per share for the current fiscal year.

Revvity Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be paid a $0.07 dividend. The ex-dividend date is Thursday, April 17th. This represents a $0.28 annualized dividend and a yield of 0.23%. Revvity’s dividend payout ratio (DPR) is 13.53%.

Revvity declared that its Board of Directors has authorized a share repurchase program on Monday, November 4th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to buy up to 6.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Revvity

In related news, insider Tajinder S. Vohra sold 5,492 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total value of $641,520.52. Following the transaction, the insider now directly owns 19,652 shares of the company’s stock, valued at approximately $2,295,550.12. The trade was a 21.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.60% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.